Daridorexant NEW

Daridorexant;1505484-82-1

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

• 
  
• Product Number: D089000
  English Name: Daridorexant
  English Alias: (S)-(2-(5-chloro-4-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone
  CAS Number: 1505484-82-1
  Molecular Formula: C₂₃H₂₃ClN₆O₂
  Molecular Weight: 450.92
• 
  
• Product Advantages: As a novel orexin receptor antagonist, Daridorexant features high selectivity and potent pharmacological activity, precisely targeting and inhibiting orexin receptors OX1R and OX2R to reduce wakefulness signaling. With a stable chemical structure, it demonstrates favorable pharmacokinetic properties in in vitro and in vivo experiments, including high plasma protein binding rate and a clear metabolic pathway, providing reliable safety and efficacy guarantees for clinical application.
• 
  
• Application Fields: It is mainly used for the treatment of adult insomnia, regulating the sleep-wake cycle by blocking orexin receptors to improve symptoms such as difficulty falling asleep and sleep maintenance disorders. In the field of drug research and development, it can be used as a reference standard for quality control, impurity analysis, and biological sample detection of related formulations. In preclinical research, it is used to evaluate the drug's efficacy, toxicity, and mechanism of action. Additionally, it can serve as a tool compound for basic medical research related to orexin receptors.
• 
  
• Background Description: Insomnia is a common sleep disorder, affecting approximately one-third of the global population. Traditional insomnia treatments have limitations such as addiction and hangover effects, while Daridorexant, as a non-benzodiazepine drug, regulates sleep by targeting the orexin system, creating a new approach for insomnia treatment. Its research and development are based on in-depth studies of the orexin neural pathway, aiming to provide safer and more effective treatment options for insomnia.
• 
  
• Research Status: Currently, Daridorexant has completed multiple Phase III clinical trials, and the results show that it can significantly improve sleep latency, total sleep time, and sleep quality in insomnia patients without obvious risk of drug dependence. Related studies are also exploring its long-term safety, application effects in special populations (such as the elderly and comorbid patients), and interactions with other drugs. Meanwhile, research on optimizing its synthesis process, developing dosage forms, and improving bioavailability continues to advance, so as to further enhance its clinical application value.

NOTE！

We can also customize related analogues and modified peptides including HPLC, MS, 1H-NMR, MS, HPLC, IR, UV, COA, MSDS.
This product is intended for laboratory use only!

WhatsAPP: +86 17386083646
E-mail: anna@molcoo.com

NEW IN STOCK!

The Molcoo Laboratory added drug impurity reference standards, including Baricitinib, Piperazine, Benzylpenicillin, Tranilast and multiple N-Nitroso drug impurities! Now available for immediate delivery!